LHRH antagonists vs LHRH agonists: Which is more beneficial in prostate cancer therapy?

Daniel Keizman, Mario A. Eisenberger

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'LHRH antagonists vs LHRH agonists: Which is more beneficial in prostate cancer therapy?'. Together they form a unique fingerprint.